by We recently compiled a list of the Why these 15 stocks will skyrocket in 2025. In this article, we’ll take a look at where Hims & Hare Health, Inc. (NYSE: HIMS) stands against the other stocks.
Stock gains always get people talking, and 2025 is no exception. Markets have been moving higher for a while due to a shift towards technical innovation. The pace may be slowing after two years of significant returns, but investors have regained confidence after the Stargate project was announced.
Small and mid-sized companies have recently started picking up pace and landing on investors’ radars, as mega-cap stocks are now trading at nose-bleed valuations. These companies have higher growth potential than their Mega-Cap rivals, which explains the sudden increase in interest.
Smaller and mid-cap stocks faced challenges in previous years as corrections and rate hikes weighed on market sentiment. However, with inflation looking more contained and Trump pushing for more rate cuts, things are looking even better for these mid-cap stocks.
Methodology
For this article, I screened the best performing year-to-date stocks in the $5 billion to $20 billion market cap bracket. Stocks I’ve recently covered are excluded from this list.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds invest in? The reason is simple: our research shows that we can outperform the market by imitating the best stock picks from the best hedge funds. Our quarterly newsletter strategy selects 14 cap and large-cap stocks each quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (See more details here).
A nurse in a telehealth platform talking to a patient on video call for consultation.
Number of hedge fund holders in Q3 2024: 31
Hims & Hers Health (NYSE: HIMS) is a telehealth company. It offers prescription and over-the-counter medications.
HIMS shares are up significantly so far in 2025, partly due to analysts raising expectations for revenue growth and profitability. This is due to new product launches. Additionally, Needham & Company reiterated its buy rating and raised its price target to $31. It named HIMS & Her a top digital health pick for the year and sees a growing lineup of weight loss treatments.
Hims & Hare also has a partnership with Eli Lilly to expand access to obesity medications and fuel growth. Q3 revenue rose 77% year over year to $400 million and adjusted EBITDA exceeded $50 million. Management also forecasts Q4 2024 revenue between $465 million and $470 million, up about 89% to 91%.
